327 related articles for article (PubMed ID: 32912633)
1. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
Fertil Steril; 2021 Feb; 115(2):397-405. PubMed ID: 32912633
[TBL] [Abstract][Full Text] [Related]
2. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study.
Harada T; Osuga Y; Suzuki Y; Fujisawa M; Fukui M; Kitawaki J
Fertil Steril; 2022 Mar; 117(3):583-592. PubMed ID: 34895700
[TBL] [Abstract][Full Text] [Related]
3. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
BMC Womens Health; 2021 Jun; 21(1):250. PubMed ID: 34154590
[TBL] [Abstract][Full Text] [Related]
4. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
Osuga Y; Enya K; Kudou K; Hoshiai H
Fertil Steril; 2019 Nov; 112(5):922-929.e2. PubMed ID: 31594635
[TBL] [Abstract][Full Text] [Related]
5. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
[TBL] [Abstract][Full Text] [Related]
6. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Brown E; Dynowski K; Wilk K; Li Y; Mathur V; Warsi QA; Wagman RB; Johnson NP
Lancet; 2022 Jun; 399(10343):2267-2279. PubMed ID: 35717987
[TBL] [Abstract][Full Text] [Related]
7. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
D'Hooghe T; Fukaya T; Osuga Y; Besuyen R; López B; Holtkamp GM; Miyazaki K; Skillern L
Hum Reprod; 2019 May; 34(5):813-823. PubMed ID: 31067329
[TBL] [Abstract][Full Text] [Related]
9. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
Blair HA
Drugs; 2024 Apr; 84(4):449-457. PubMed ID: 38592603
[TBL] [Abstract][Full Text] [Related]
10. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis.
Yan H; Shi J; Li X; Dai Y; Wu Y; Zhang J; Gu Z; Zhang C; Leng J
Fertil Steril; 2022 Dec; 118(6):1102-1116. PubMed ID: 36283862
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
[TBL] [Abstract][Full Text] [Related]
13. Relugolix: First Global Approval.
Markham A
Drugs; 2019 Apr; 79(6):675-679. PubMed ID: 30937733
[TBL] [Abstract][Full Text] [Related]
14. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial.
Donnez J; Taylor HS; Taylor RN; Akin MD; Tatarchuk TF; Wilk K; Gotteland JP; Lecomte V; Bestel E
Fertil Steril; 2020 Jul; 114(1):44-55. PubMed ID: 32505383
[TBL] [Abstract][Full Text] [Related]
15. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
16. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial.
Hoshiai H; Seki Y; Kusumoto T; Kudou K; Tanimoto M
BMC Womens Health; 2021 Oct; 21(1):375. PubMed ID: 34711224
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study).
Kitade M; Kumakiri J; Kobori H; Murakami K
Trials; 2024 May; 25(1):343. PubMed ID: 38790029
[TBL] [Abstract][Full Text] [Related]
18. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
19. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis.
Xin L; Ma Y; Ye M; Chen L; Liu F; Hou Q
Arch Gynecol Obstet; 2023 Oct; 308(4):1047-1056. PubMed ID: 36656435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
